Not sure why there is a debate here over the results … strong growth recorded, material improvement in sales in July 2024 compared to last July with solid growth forecasted for rest of the FY. Changes to reimbursement to significantly benefit Eye by year’s end. A lot of positives in the result.
Patient holders should hopefully be rewarded in due time.
Not sure why there is a debate here over the results … strong...
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $40.08M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 17.0¢ | $14.83K | 86.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8892 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 22000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| EYE (ASX) Chart |